BLSM
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc. (BLSM) has 9 SEC Form 4 filings (21 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 12, 2026.
Insiders have net bought $25.2M over the trailing 6 months. The largest single insider purchase in this window was $10.0M by Director ORBIMED ADVISORS LLC on Aug 10, 2026.
- Industry:Biotechnology
- CEO:Jing Rong Jean Cui
- HQ:San Diego, CA, US
- IPO:2026-08-07
Insider Buying
$25.2M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Purchase | 625,000 | $10.0M | Aug 12 | SEC ↗ | |
| Director | Purchase | 625,000 | $10.0M | Aug 12 | SEC ↗ | |
Schmid John P.First in 4 months | Director | Purchase | 6,000 | $96K | Aug 10 | SEC ↗ |
Chen BihuaFirst in 6 months | Director, 10% Owner | Purchase | 312,500 | $5.0M | Aug 10 | SEC ↗ |
Keyes Jason AFirst filing | Chief Financial Officer | Purchase | 700 | $11K | Aug 10 | SEC ↗ |
Liptak Vincent PaulFirst filing | General Counsel | Purchase | 2,500 | $40K | Aug 10 | SEC ↗ |
Liptak Vincent PaulFirst filing | General Counsel | Purchase | 2,200 | $35K | Aug 10 | SEC ↗ |
Related companies
BlossomHill Therapeutics, Inc. is in the Healthcare sector.